期刊
PEDIATRIC BLOOD & CANCER
卷 57, 期 6, 页码 1018-1024出版社
WILEY PERIODICALS, INC
DOI: 10.1002/pbc.23124
关键词
vascular anomalies; vascular malformations; kaposiform hemangioendothelioma; Kasabach-Merritt phenomenon; lymphatic malformation; rapamycin; sirolimus
Background. Vascular anomalies comprise a diverse group of diagnoses. While infantile hemangiomas are common, the majority of these conditions are quite rare and have not been widely studied. Some of these lesions, though benign, can impair vital structures, be deforming, or even become life-threatening. Vascular tumors such as kaposiform hemangioendotheliomas (KHE) and complicated vascular malformations have proven particularly difficult to treat. Procedure. Here we retrospectively evaluate a series of six patients with complicated, life-threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies. Results. These patients showed significant improvement in clinical status with tolerable side effects. Conclusions. Sirolimus appears to be effective and safe in patients with life-threatening vascular anomalies and represents an important tool in treating these diseases. These findings are currently being further evaluated in a Phase II safety and efficacy trial. Pediatr Blood Cancer 2011; 57: 1018-1024. (C) 2011 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据